Peer reviewed

Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-5)

Phase 3 trial comparing tirzepatide to semaglutide as add-on therapy in Type 2 diabetes, demonstrating greater A1C and weight reductions with tirzepatide.

New England Journal of MedicinePublished 2023-02-01Accessed 2026-07-08

Open original source

Registry record

Source metadata

Publisher: New England Journal of Medicine
Source type: Peer reviewed
Registry ID: nejm-tirzepatide-surpass5-2023

Source usage

Linked from 1 page

Comparison

Tirzepatide vs Semaglutide

Interpretation boundary

What this record can and cannot establish

Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.